Ascendis Pharma A/S ADR (NASDAQ:ASND) price on Friday, April 11, rose 5.34% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $150.99.
A look at the stock’s price movement, the close in the last trading session was $143.33, moving within a range at $142.18 and $153.335. The beta value (5-Year monthly) was 0.536. Turning to its 52-week performance, $169.37 and $111.09 were the 52-week high and 52-week low respectively. Overall, ASND moved -0.87% over the past month.
Ascendis Pharma A/S ADR’s market cap currently stands at around $9.04 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-Feb-11.
Analysts have a consensus estimate of 93.49M for the company’s revenue for the quarter, with a low and high estimate of 83M and 107M respectively. The average forecast suggests down to a -2.51% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 575.49M, representing a 58.26% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ASND is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
7 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 6 recommend ASND as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ASND’s current price about -2.29% and 2.38% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 51.38, while 7-day volatility ratio is 12.09% and 6.16% in the 30-day chart. Further, Ascendis Pharma A/S ADR (ASND) has a beta value of 0.45, and an average true range (ATR) of 9.80. Analysts have given the company’s stock an average 52-week price target of $180, forecast between a low of $180 and high of $180. Looking at the price targets, the low is -19.21% off current price level while to achieve the yearly target high, price needs to move -19.21%. Nonetheless, investors will most likely welcome a -19.21% jump to $180 which is the analysts’ median price.
If we refocus on Ascendis Pharma A/S ADR (NASDAQ:ASND), historical trading data shows that trading volumes averaged 0.65 over the past 10 days and 508.75K over the past 3 months. The company’s latest data on shares outstanding shows there are 59.84 million shares.
The 0.78% of Ascendis Pharma A/S ADR’s shares are in the hands of company insiders while institutional holders own 106.77% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 4.38 million on 2025-03-14, giving us a short ratio of 8.89. The data shows that as of 2025-03-14 short interest in Ascendis Pharma A/S ADR (ASND) stood at 877.99996 of shares outstanding, with shares short rising to 3.63 million registered in 2025-02-14. Current price change has pushed the stock 9.68% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ASND stock continues to rise going into the next quarter.
